This study includes subjects with Progressive Supranuclear Palsy (PSP). Subjects were enrolled in the davenutide PSP Phase Trail 2/3. Additional subjects were clinically diagnosed PSP at the University of California, San Francisco Memory and Aging Center.

Participants met the modified Neuroprotection and Natural History in Parkinson Plus Syndrome study criteria for PSP.

See for comprehensive inclusion and exclusion criteria.

Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676-685. doi:10.1016/S1474-4422(14)70088-2. PMID: 24873720